drug

fosaprepitant

1 story · latest Nov 9, 2026

Follow fosaprepitant. Every new filing, FDA action, and trial change, in your feed and a morning email, each linked to its source.

Follow free for 14 daysNo card.

Status: FDA approved Jan 2008 · NDA022023, NDA210064, NDA216686, NDA220436
Brands: Focinvez, Fosaprepitant Dimeglumine, Navitrux

Relationships

Developed by Teva Pharmaceutical Industries Ltd

Developed by Merck & Co., Inc.

Timeline

Bicara reaches substantial enrollment in HPV-negative head and neck cancer trial

Nov 9Quarterly updateBicara Therapeutics Compass Therapeutics

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.